1. Mitochondrial form and function Jonathan R. Friedman  & Jodi Nunnari Nature Bd. 505, Seiten 335–343 (16. Januar 2014) 
  2. Evolutionary biology: essence of mitochondria. Henze K, Martin W; Martin, William Nature. 426 (6963): 127–8 (2003). 
  3. NIH Duchenne and Becker muscular dystrophy information page https://ghr.nlm.nih.gov/condition/duchenne-and-becker-muscular-dystrophy
  4. Bushby K1, Finkel R, Birnkrant DJ, Case LE, Clemens et al,.Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010 Jan;9(1):77-93.
  5. NCBI Genetic Testing Registry https://www.ncbi.nlm.nih.gov/gtr/tests/509306/
  6. https://en.wikipedia.org/wiki/Spirometry 
  7. Pulmonary-Function Testing Robert O. Crapo N. Eng J Med 1994; 331:25-30
  8. Mordente A, Martorana G, Minotti G et al. Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1, 4-benzoquinone (idebenone). Chem Res Toxicol. 1998;11(1):54–63
  9. Bach, J.R., Ishikawa, Y., and Kim, H. Prevention of pulmonary morbidity for patients with Duchenne muscular dystrophy. Chest. 1997; 112: 1024-1028
  10. Gozal, D. Pulmonary manifestations of neuromuscular disease with special reference to Duchenne muscular dystrophy and spinal muscular atrophy. Pediatr Pulmonol. 2000; 29: 141-150
  11. Matthews E, Brassington R, Kuntzer T,et al., Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database of Systematic Reviews. 5. Mai 2016
  12. McDonald CM, Meier T, Voit T et al,. Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy. Neuromuscul Disord. 2016 Aug; 
  13. Mayer, Oscar H. et al. „Efficacy of Idebenone to Preserve Respiratory Function above Clinically Meaningful Thresholds for Forced Vital Capacity (FVC) in Patients with Duchenne Muscular Dystrophy.” Journal of Neuromuscular Diseases 4.3 (2017):
    189–198. PMC. Web. Donnerstag, 31. Mai 2018
  14. Winck J.C, LeBlanc C, Soto J.L, Plano F.The value of cough peak flow measurements in the assessment of extubation or decannulation readiness. Rev Port Pneumol. 2015 Mar-Apr 
  15. https://en.wikipedia.org/wiki/Oxygen_saturation_(medicine)
  16. Phillips MF, Quinlivan RC, Edwards RH, Calverley PM. Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. Am J Respir Crit Care Med 2001; 164:2191–2194
  17. Richardson M, Moulton K, Rabb D et al. Capnography for Monitoring End-Tidal CO2 in Hospital and Pre-hospital Settings: A Health Technology Assessment [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Mar. (CADTH Health Technology Assessment, No. 142.)
  18. ClinicalTrials.gov. Santhera, Duchenne muscular dystrophy. https://clinicaltrials.gov/ct2/results?cond=Duchenne+Muscular+ Dystrophy&term=santhera&cntry1=&state1=&Search=Search.